The once-daily pill also helped 75 per cent of patients who received the highest dose of orforglipron lower their A1C level - ...

(Reuters) -Eli Lilly said on Tuesday its experimental GLP-1 pill helped overweight adults with type 2 diabetes shed 10.5% of ...

Stocks closed higher Tuesday as investors brushed aside concerns about the potential impact of President Donald Trump's ...

Novo Nordisk NVO suffered a major setback in July after slashing its 2025 sales and profit outlook, triggering a decline in ...

In a study of more than 1,600 adults with type 2 diabetes, those who received the highest dose of orforglipron on average shed 10.5% of their weight.

Eli Lilly says its weight loss pill orforglipron could win approval this year after a trial showed over 10% weight loss in ...

Makers of weight-loss drugs are expected to rake in more than $150 billion in revenue by the early 2030s, thanks to the ever-growing popularity of Eli Lilly's Zepbound and Novo Nordisk's Wegovy.

The weight-loss pill has excellent potential in the hot market for such drugs. Well before market open, Eli Lilly announced ...

Novo Nordisk said on Monday it is offering its diabetes drug Ozempic for $499 per month to eligible cash-paying type 2 ...

GLP-1 drugs may lower the risk of some obesity-related cancers, according to an observational study of people who were ...

Amgen's stock is up 13.5% in 2025, fueled by strong drug sales and new biosimilars, but looming competition and pricing ...